Seattle-based biotech A-Alpha Bio has received $2.4 million from the Department of Defense (DOD) in a joint project with Lawrence Livermore National Laboratory (LLNL).
A-Alpha Bio and LLNL have been working together over the last year on the joint project focused on antibody discovery. They have measured protein interactions between antibodies and coronavirus variants and will switch gears to focus on five pathogen families that are considered biological threats by the government.
“Based on our experience working with the LLNL team and the computational resources and knowhow that they bring, we are excited to tackle multiple pathogen families beyond Covid,” said David Younger, co-founder and CEO of A-Alpha Bio.